Nyxoah SA
$3.23
▲
12.3%
2026-04-21 08:34:00
www.nyxoah.com
NGM: NYXH
Explore Nyxoah SA stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$121.16 M
Current Price
$3.23
52W High / Low
$8.87 / $2.35
Stock P/E
—
Book Value
$1.33
Dividend Yield
—
ROCE
-119.32%
ROE
-1.11%
Face Value
—
EPS
$-2.76
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
—
Beta
0.87
Debt / Equity
85.64
Current Ratio
1.25
Quick Ratio
1.16
Forward P/E
-1.9
Price / Sales
12.46
Enterprise Value
$118.95 M
EV / EBITDA
-1.44
EV / Revenue
11.87
Rating
None
Target Price
$10.9
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Sanara MedTech Inc. | $20.62 | — | $190.4 M | — | 16.84% | -1.75% | $35.95 / $16.05 | $0.66 |
| 2. | Hologic, Inc. | NOT FOUND | — | — | — | 9.77% | 10.86% | $76.07 / $51.9 | $23.51 |
| 3. | OraSure Technologies, Inc. | $3.19 | — | $221.2 M | — | -18.75% | -18.3% | $3.82 / $2.08 | $4.84 |
| 4. | Bausch + Lomb Corporation | $16.76 | — | $5.94 B | — | 1.55% | -5.39% | $18.91 / $10.45 | $18.2 |
| 5. | Anbio Biotechnology | $26.98 | 380.56 | $3.88 B | — | 11.61% | 27.05% | $55.65 / $6.05 | $0.63 |
| 6. | Embecta Corp. | $9.6 | 4.08 | $568.51 M | 6.25% | 35.74% | -13.73% | $15.55 / $8.47 | $-10.35 |
| 7. | BioLife Solutions, Inc. | $22.19 | — | $1.04 B | — | -4.34% | -3.37% | $29.62 / $17.86 | $7.72 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 5.64 M | 1.97 M | 1.34 M | 1.06 M | 1.26 M | — |
| Operating Profit | -18.26 M | -24.2 M | -19.85 M | -20.64 M | -18.31 M | — |
| Net Profit | -23.51 M | -23.58 M | -20.61 M | -22.38 M | -17.15 M | — |
| EPS in Rs | -0.54 | -0.54 | -0.47 | -0.51 | -0.39 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 10.02 M | 4.52 M | 4.35 M | 3.08 M |
| Operating Profit | -82.94 M | -58.81 M | -45.1 M | -32.5 M |
| Net Profit | -90.08 M | -59.24 M | -43.21 M | -31.23 M |
| EPS in Rs | -2.06 | -1.36 | -0.99 | -0.72 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 118.47 M | 158.41 M | 124.16 M | 146.07 M |
| Total Liabilities | 69.34 M | 45.15 M | 26.14 M | 25.75 M |
| Equity | 49.13 M | 113.25 M | 98.02 M | 120.32 M |
| Current Assets | 61.21 M | 98.08 M | 68.35 M | 100.26 M |
| Current Liabilities | 48.96 M | 21.53 M | 14.44 M | 14.91 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -68.98 M | -49.23 M | -44.78 M | -28.76 M |
| Investing CF | 28.33 M | -16.32 M | 32.01 M | -89.95 M |
| Financing CF | 38.11 M | 77.44 M | 16.86 M | -0.98 M |
| Free CF | -72.75 M | -55.3 M | -55.74 M | -45.1 M |
| Capex | -3.77 M | -6.07 M | -10.96 M | -16.35 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 121.63% | 3.98% | 40.99% | — |
| Earnings Growth % | -52.08% | -37.08% | -38.39% | — |
| Profit Margin % | -899.05% | -1310.24% | -993.84% | -1012.48% |
| Operating Margin % | -827.76% | -1300.8% | -1037.3% | -1053.79% |
| Gross Margin % | 63.13% | 65.67% | 61.91% | 62.71% |
| EBITDA Margin % | -827.36% | -1168.5% | -967.8% | -904.25% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.